Comparing a new drug to topotecan for relapsed small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug, JK-1201I, against a standard treatment (topotecan) for people with extensive-stage small cell lung cancer that came back after platinum-based chemotherapy. It aims to see if the new drug works better at controlling the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You have small cell lung cancer that has spread widely (extensive stage) and has returned after one prior platinum-based chemotherapy.
- You have at least one tumor that can be measured on scans.
- Your daily activity level is good (ECOG score 0 or 1, meaning you can care for yourself and are up and about).
- You have not had a topoisomerase I inhibitor (like irinotecan or topotecan) before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called HS-20093 against a standard drug (topotecan) for people with small cell lung cancer that has returned after initial treatment. The goal is to see which drug works better.
This trial tests whether adding IBB0979 (an experimental immunotherapy) to standard chemotherapy (topotecan) works better than topotecan alone for people whose small cell lung cancer has returned or worsened after prior treatment. It aims to find a new option for patients who have limited options.
This study tests a new drug, ifinatamab deruxtecan, against the doctor's choice of standard treatments for people with extensive-stage small cell lung cancer that has returned after initial platinum-based chemotherapy. The goal is to see if the new drug works better and if it might be a new option for you.
This study compares a new drug called ZG006 against standard chemotherapy for people with small cell lung cancer that has come back after prior treatment. The goal is to see if ZG006 works better or has fewer side effects.
This trial tests a new drug, ZL-1310, against standard treatments for people with small cell lung cancer that has returned after initial therapy. The goal is to see if ZL-1310 works better than other options.
This study tests a new drug (GSK5764227) for people whose extensive-stage small cell lung cancer has gotten worse after platinum chemotherapy combined with immunotherapy. The goal is to see if this targeted treatment can help shrink tumors and control the cancer.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.